Hyemin Pomerantz is a Dermatology physician. OpenAlex indexes 33 publications with 446 citations (h-index 12); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
70 Hastings St Ste Ll-2
Wellesley, MA 024815439
Telephone
781-261-0085Provider last certified this registry record 9 Nov 2022.
Clinical trials
- AV-23-001 AVAVA MIRIA Pilot Study
Sponsor: AVAVA, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
24 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year202524 payments
- Lilly USA, LLCProgram year202517 payments
- ABBVIE INC.Program year202518 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
28.2%Azole Antifungal14.1%Ketoconazole100%Part D≥23 patientsFirst-generation cephalosporins10%Cephalexin100%Part D≥22 patients+ 1 more class in this area
Dermatology
23%Corticosteroid12.7%Triamcinolone Acetonide100%Part D≥32 patientsInterleukin-4 Receptor alpha Antagonist10.3%Dupixent Pen100%Part D<11 patientsSensory organs
22%Corticosteroid22%Betamethasone Diprop Augmented75%Hydrocortisone25%Part D≥33 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Treating Acne Scars in Fitzpatrick Skin Types I–VI Using a Novel 1550 nm Non‐Ablative Resurfacing Laser With Focal Point Technology
Journal of Cosmetic Dermatology
2025 - Focal point technology: Controlling treatment depth and pattern of skin injury by a novel highly focused laser
Journal of the American Academy of Dermatology
2024 - Vascular characteristics of port wine birthmarks as measured by dynamic optical coherence tomography
Journal of the American Academy of Dermatology
2021
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Robert Modlin, MD
University of California, Los Angeles
Heidi Kong, MD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Jon Hanifin, MD
Oregon Health & Science University (OHSU)
Victoria Werth, MD
Perelman School of Medicine at the University of Pennsylvania
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”